CAR-T treatment for HIV and aggressive B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial studies a lab-made immune cell treatment (CAR-T) for adults who have HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It aims to see if the treatment can control the lymphoma safely in this specific group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and can sign consent before any study steps.
- You have HIV that is controlled (viral load under 50 copies/mL) and you can stay on your HIV medicines during the study.
- Your lymphoma is a specific type of B-cell non-Hodgkin lymphoma (such as diffuse large B-cell, high-grade, primary mediastinal, or follicular grade 3B).
- Your lymphoma has come back or not responded after at least 2 treatment “rounds,” including chemotherapy with an anthracycline and rituximab (or another CD20-targeted drug).
- You have measurable disease (PET scan shows active lymphoma or a bone marrow biopsy shows lymphoma).
- You meet key organ/health limits (such as adequate heart, lung, kidney, liver, and blood counts) and you can safely have leukapheresis (blood cell collection).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
This trial tests a combination of two medications (golcadomide and rituximab) as a short-term treatment to shrink lymphoma before you receive CAR T-cell therapy. The goal is to make the CAR T treatment more effective for people whose lymphoma has come back or hasn't responded to previous treatments.
This trial tests a special immune cell therapy (CAR-T cells) for people with a type of aggressive lymphoma that returned more than a year after first treatment. It aims to see if this therapy can help control the cancer again.
This trial tests a two-step treatment for patients with an aggressive type of blood cancer (large B-cell lymphoma) that has come back or didn't respond well to standard therapy. You'll receive a stem cell transplant followed by CAR-T cells—specially engineered immune cells designed to fight cancer.
This early-stage trial tests an automated version of axicabtagene ciloleucel (a CAR-T cell therapy) for large B-cell lymphoma that has come back or stopped responding to initial chemotherapy. CAR-T therapy uses your own immune cells, modified in a lab to fight cancer cells.
Hear when a new Recurrent Diffuse Large B-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.